December 3, 2020 | Jen Temple, Head of Communications | Reading Time: < 1 minute
Canexia Health’s Co-Founder and Chief Medical Officer David Hunstman was recently interviewed by OncLive as part of their OncLive On Air Podcast. OncLive is a digital platform that offers resources and information to oncology professionals that they can use to help provide the best patient care.
In this exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.
July 20, 2021
Canexia Health recently sponsored a virtual roundtable, hosted by GenomeWeb, focused on disparities in access to precision oncology. Kellie Jack of Weill Cornell Medicine, Raymond Osarogiagbon of Baptist Cancer Center, Rachit Kumar of Maine General Medical Center, and Greg Tranah of Sutter Health discussed their perspectives working within small and large health systems across the US.
July 13, 2021
Liquid biopsy has become a useful tool for targeted cancer treatment selection.
June 22, 2021
Last year, by Precision Oncology News’ count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.